Amgen Can't Amend Petition To Address Potential Double Tax
Drugmaker Amgen isn't entitled to amend its petition to protect against possible double taxation after an eight-week trial and briefing in its income-allocation case already have been completed, the U.S. Tax Court...To view the full article, register now.
Already a subscriber? Click here to view full article